MAPT and Alzheimer disease: Diagnosis of AD is usually based on clinical criteria, but may be supported by biochemical markers such as a decreased amyloid-β (Aβ) 42 [3], and increased Aβ oligomer [4, 5] and tau protein in cerebrospinal fluid (CSF) [3].